Apr 08, 2020
Immutep’s Partner, EOC Pharma, Continues to Advance Efti in Breast Cancer
Mar 24, 2020
Immutep Reports Supportive Efficacy Data from the Phase IIb AIPAC Study; Overall Survival Data Expected in Late 2020
Mar 18, 2020
Immutep’s Partner, EOC Pharma, Reports Completion of Recruitment of Phase I Study of Efti
Mar 08, 2020
Immutep Receives Second IND Approval for Efti from US FDA
Feb 18, 2020
Immutep Reports Positive TACTI-002 Data
Feb 04, 2020
Immutep to Present TACTI-002 Interim Data at German Cancer Congress
Jan 29, 2020
Immutep Activities Report
Jan 08, 2020
Immutep Expands Part C of TACTI-002 Due to Positive Data
Dec 18, 2019
INSIGHT-004 Clinical Trial Update
Nov 13, 2019
Immutep Announces European Patent Grant for LAG525 Antibody
Nov 07, 2019
Immutep Presents Positive Interim Data from Phase II TACTI-002 Trial at SITC
Oct 28, 2019
Operational Update
